The Validity of Body Mass Index Criteria in Obese School-Aged Children

Komiya, Hideaki; Masubuchi, Yuko; Mori, Yutaka; Tajima, Naoko

doi:10.1620/tjem.214.27

Cited by 18 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In three patients, maintenance therapy with MMF was also continued. In ten patients, RTX infusion for a mean followup period of 17 (range 13-21) months), resulted in a reduction of the mean PSL dose from 0.39±0.18 to 0.15± 0.14 mg/kg per day (63% reduction, p<0.01), the mean 12-month relapse rates from 4.1±1.7 to 0.6±0.6 episodes (86% reduction, p<0.01), and the obesity index, which is defined by the formula: (measured weight -ideal body weight) / ideal body weight × 100% [12] from 8.9±20.5 to 1.9± 12.5% (p<0.05).…”

Section: Resultsmentioning

confidence: 99%

Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine

et al. 2010

View full text Add to dashboard Cite

Rituximab (RTX) has been successfully used as a rescue therapy in children with steroid-dependent nephrotic syndrome (SDNS). However, little is known regarding maintenance therapy after a successful response to RTX in such patients. The efficacy and safety of a single RTX infusion (375 mg/m(2)) were assessed in ten patients who had persistent SDNS associated with minimal-change disease (MCD) despite the long-term use of cyclosporine (CsA). The mean follow-up after RTX infusion was 17 months. Applying RTX resulted in a significant reduction in the mean prednisolone (PSL) dose from 0.39 +/-0.18 to 0.15 +/- 0.14 mg/kg per day. The mean 12-month relapse rates significantly decreased from 4.1 +/- 1.7 to 0.6 +/- 0.6. All but one patient who had continued CsA as maintenance therapy after a single RTX infusion were able to withdraw from PSL without any relapses during the study period, whereas the remaining five patients who discontinued CsA experienced relapses after CD19 cells re-emerged, leading to the reintroduction of CsA or an additional RTX infusion. Infusion reactions occurred in five of ten patients. These data indicate that a single RTX infusion may improve response to CsA in patients with persistent SDNS due to the phenomenon of secondary resistance to CsA.

show abstract

Section: Resultsmentioning

confidence: 99%

Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine

et al. 2010

View full text Add to dashboard Cite

show abstract

“…1). The mean obesity index was defined by the formula: ðmeasured weight À ideal body weightÞ= ideal body weight Â 100% [9]. On the other hand, no statistical difference was found in the mean standard deviation (SD) score for height of the patients at final observation in comparison to that at the start of treatment Fig.…”

Section: Resultsmentioning

confidence: 99%

Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration

et al. 2010

View full text Add to dashboard Cite

Although cyclosporine (CsA) therapy is effective in the management of children with steroid-dependent nephrotic syndrome (SDNS), a recent study has revealed that the use of CsA itself was a significant predictor of NS relapse in adulthood. The efficacy of single daily high-dose mizoribine (MZR) therapy was assessed in 10 children with SDNS (mean age, 6.2 years) who had never been treated with CsA previously. MZR was started at 5 mg/kg, administered as a single daily dose after breakfast, and the dose was adjusted to achieve 2-h post-dose MZR levels (C2) of approximately 3 μg/ml. In 9 of the 10 patients, treatment with a single daily dose of MZR (mean dose, 8.4 mg/kg/day) over a period of 22 months (median) resulted in significant reduction of the mean prednisolone dose from 0.39 to 0.15 mg/kg/day and the median 12-month relapse rate from 3.0 to 0.4 episodes/12 months. Although cyclophosphamide was initiated in one patient because of treatment failure, none of the 10 patients required treatment with CsA during the observation period (median, 33 months). These data indicate that single daily high-dose MZR therapy is possibly useful in treating children with SDNS and that it may also eliminate the need for CsA in some patients.

show abstract

“…It is possible, however, that the use of BMI as a predictor of obesity could result in misclassification of obesity status, particularly for taller children [20]. Although there has been debate regarding the validity of the 95th percentile cutoff point for obesity among children and adolescents [20][21][22][23][24], it has been reported that the Center for Disease Control and Prevention cutoff points for obesity based on BMI, which the current study used, has high sensitivity and specificity for determining obesity even in school-aged children [21,23].…”

Section: Discussionmentioning

confidence: 99%